Wells Fargo & Company Krystal Biotech, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KRYS
# of Institutions
276Shares Held
24.9MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$674 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$490 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$416 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$228 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$174 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.38B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...